| Name | Title | Contact Details |
|---|---|---|
Spencer Clark |
SVP and General Counsel | Profile |
Roxanne Womack |
SVP, Chief Compliance Officer | Profile |
Spencer Clark |
VP and Senior Legal Counsel | Profile |
Kelly Whelan |
VP and Senior Legal Counsel, American and Eastern Groups | Profile |
We are on the leading edge of research, development, clinical trials, and implementation of digital solutions that are aimed at harm reduction for various public health challenges. Our goal is to reduce harm and prevent unintentional deaths for people of all ages. Our team has pioneered apps that were developed in response to the opioid crisis, which is now a world-wide problem, as well as the COVID-19 pandemic and health & safety concerns in senior care centers.
isogenix is a Chandler, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Inovise Medical is a Beaverton, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Gateway Healthcare (GHI) is a non-profit behavioral health care organization that provides a wide array of services to adults, children and families in Rhode Island. We provide services to people of all cultural and economic backgrounds, who may not
Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.